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PURPOSE. The Pakistan Punjab population has been a rich source for identifying genes causing
or contributing to autosomal recessive retinal degenerations (arRD). This study was carried
out to delineate the genetic architecture of arRD in the Pakistani population.
METHODS. The genetic origin of arRD in a total of 144 families selected only for having
consanguineous marriages and multiple members affected with arRD was examined. Of these,
causative mutations had been identified in 62 families while only the locus had been identified
for an additional 15. The remaining 67 families were subjected to homozygosity exclusion
mapping by screening of closely flanking microsatellite markers at 180 known candidate
genes/loci followed by sequencing of the candidate gene for pathogenic changes.
RESULTS. Of these 67 families subjected to homozygosity mapping, 38 showed homozygosity
for at least one of the 180 regions, and sequencing of the corresponding genes showed
homozygous cosegregating mutations in 27 families. Overall, mutations were detected in
approximately 61.8 % (89/144) of arRD families tested, with another 10.4% (15/144) being
mapped to a locus but without a gene identified.
CONCLUSIONS. These results suggest the involvement of unmapped novel genes in the remaining
27.8% (40/144) of families. In addition, this study demonstrates that homozygosity mapping
remains a powerful tool for identifying the genetic defect underlying genetically heteroge-
neous arRD disorders in consanguineous marriages for both research and clinical applications.
Keywords: homozygosity mapping, genetic analysis, autosomal recessive retinal dystrophies,
consanguineous
Hereditary retinal dystrophies (RD) constitute a group ofinherited retinal diseases characterized by chronic and
progressive visual impairment, genetic heterogeneity, and
significant clinical overlap among the different disorders. To
date, mutations in more than 200 genes are known to cause the
different forms of RD1 as summarized in RetNet (https://sph.
uth.edu/Retnet/; in the public domain). Retinal dystrophies can
be inherited as autosomal recessive (ar), autosomal dominant
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TABLE 1. Summary of Microsatellite Markers for Homozygous Mapping
No. Gene/Locus
Inheri-
tance Diseases Location Mb, GRCh37 Transcript ID
Marker
1
Distance,
Mb
Marker
2
Distance,
Mb
1 ABCA4 AR SMD, RP,
CRD, FF
1p22.1 94.46–94.59 NM_000350.2 D1S2779 0.76
2 ABHD12 AD US 20p11.21 25.28–25.37 NM_001042472 D20S844 0.83
3 ADAM9 AR CRD 8p11.22 38.85–38.96 NM_003816.2 D8S1791 0.7
4 AIPL1 AR/AD LCA, CRD 17p13.2 6.33–6.34 NM_014336.3 D17S796 0.08
5 ARL2BP AR RP 16q13 57.28–57.29 NM_012106.3 D16S3057 0.24
6 BBIP1 AR BBS 10q25.2 112.66–112.68 NM_001195306 D10S597 1.43 D10S1682 0.64
7 BBS1 AR BBS, RP 11q13.1 66.28–66.30 NM_024649.4 D11S913 0.34 D11S1889 1.01
8 BBS10 AR BBS 12q21.2 76.74 NM_024685.3 D12S1684 0.52
9 BBS12 AR BBS 4q27 123.65–123.67 NM_001178007.1 D4S430 0.04
10 BBS2 AR BBS, RP 16q21 56.52–56.55 NM_031885.3 D16S3140 0.21
11 BBS3 AR BBS 3q11.2 97.48–97.52 NM_032146.3 D3S1603 0.94 D3S3619 1.84
12 BBS4 AR BBS 15q22.3-q23 72.98–73.03 NM_033028.4 D15S980 0.08
13 BBS5 AR BBS 2q31.1 170.34–170.36 NM_152384.2 D2S2284 1.13 D2S2345 1.62
14 BBS7 AR BBS 4q27 122.75–122.79 NM_176824.2 D4S1612 0.43 D4S2985 1.43
15 BBS8 AR RP, BBS 14q31.3 89.29–89.34 NM_144596.2 D14S1058 0.64
16 BBS9 AR BBS 7p14 33.17–33.65 NM_198428.2 D7S2252 1.1
17 BCAMD AD MD 6p12.3-q16 49.18–94.76 N/A D6S456 0
18 BEST1 AR/AD RP, MD, ARB 11q12.3 61.72–61.73 NM_004183.3 D11S1765 0.94
19 C12orf65 AD OA 12q24.31 123.72–123.74 NM_152269.4 D12S1612 1.17
20 C1QTNF5 AD MD 11q23.3 119.21–119.22 NM_015645.3 D11S4171 0.16 D11S4104 0.57
21 C21orf2 AD CRD 21q22.3 45.75–45.76 NM_004928.2 D21S1890 0.9
22 C2orf71 AR RP 2p23.2 29.28–29.30 NM_001029883 D2S170 0.07
23 C8orf37 AD CRD, RP 8q22.1 96.26–96.28 NM_177965.3 D8S1699 0.25
24 CA4 AD RP 17q23 58.23–58.26 NM_000717.3 D17S1604 0.25
25 CABP4 AR CSNB, LCA 11q13.2 67.22–67.23 NM_145200.3 D11S1889 0.08
26 CACD AD RP, MD, CRD,
LCA
17p13 5.13–8.20 N/A D17S1832 0
27 CACNA2D4 AR CD 12p13.33 1.90–2.03 NM_172364.4 D12S100 0.15
28 CAPN5 AD NIV 11q14 76.78–76.84 NM_004055.4 D11S911 0.61
29 CDH23 AR US 10q23.1 73.16–73.58 NM_022124.5 D10S1650 0
30 CDH3 AR MD 16q22.1 68.68–68.73 NM_001793.4 D16S496 0.22
31 CDHR1 AR CRD 10q23.1 85.95–85.98 NM_033100.2 D10S1686 0.38
32 CEP290 AR SLSN, LCA 12q21.32 88.44–88.54 NM_025114.3 D12S1598 0.99
33 CERKL AR RP, CRD 2q31.3 182.40–182.52 NM_001030311.2 D2S2310 0.23
34 CFH AD MD 1q32 196.62–196.72 NM_000186.3 D1S2757 1.88
35 CIB2 AD US 15q24 78.40–78.42 NM_006383.2 D15S1023 0.72
36 CLRN1 AR US, RP 3q25 150.64–150.69 NM_174878.2 D3S1279 0.34
37 CNGA1 AR RP 4p12 47.94–48.01 NM_000087.3 D4S3002 0.6 D4S396 1.62
38 CNGA3 AR A, CRD 2q11.2 98.96–99.02 NM_001298.2 D2S2311 0 D2S113 1.68
39 CNGB1 AR RP 16q13 57.92–58.01 NM_001297.4 D16S3057 0.39
40 CNGB3 AR A, CD 8q21.3 87.59–87.76 NM_019098.4 D8S271 0.76
41 CNNM4 AR CRD 2q11.2 97.43–97.48 NM_020184.3 D2S113 0.15
42 CODA1 AD CODA 12q13.13-q14.3 53.89–67.36 N/A D12S329 0
43 CORD17 AD CRD 10q26 122.32–129.09 N/A D10S1757 0
44 CRB1 AR/AD LCA, RP 1q31.3 197.17–197.45 NM_201253.2 D1S2816 0.52 D1S2840 0.81
45 CRX AR/AD CRD, LCA,
RP
19q13.32 48.33–48.35 NM_000554.4 D19S596 0.9
46 CYP4V2 AR BCD, RP 4q35.2 187.11–187.13 NM_207352.3 D4S426 1.98
47 DFNB31 AR US 9q32 117.16–117.27 NM_015404.3 D9S1776 0.69
48 DHDDS AR RP 1p36.11 26.76–26.80 NM_024887.3 D1S2885 0.62
49 DHX38 AD RP 16q22 72.13–72.15 NM_014003.3 D16S3106 0.04
50 DTHD1 AD LCA 4p14 36.28–36.35 NM_001136536 D4S2950 1.39
51 EFEMP1 AD MD 2p16 56.09–56.15 NM_001039348 D2S378 1.15
52 ELOVL4 AD MD 6q14 80.62–80.66 NM_022726.3 D6S460 0.27
53 EMC1 AD RP 1p36.13 19.54–19.58 NM_015047.2 D1S199 0.38
54 EVR3 AD FEVR 11p13-p12 25.94–36.78 N/A D11S1751 0
55 EYS AR RP 6q12 64.43–66.42 NM_001142800.1 D6S402 1.46
56 FAM161A AR RP 2p15 62.05–62.08 NM_032180.2 D2S2206 0.44
57 FSCN2 AD RP, MD 17q25 79.5 NM_001077182 D17S928 0.75
58 FZD4 AD FEVR 11q14.2 86.66–86.67 NM_012193.3 D11S1887 0.27
59 GDF6 AD LCA, KFS 8q22.1 97.15–97.17 NM_001001557 D8S1822 0.42
60 GNAT1 AD CSNB 3p21 50.23–50.24 NM_144499.2 D3S3629 0.65
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TABLE 1. Continued
No. Gene/Locus
Inheri-
tance Diseases Location Mb, GRCh37 Transcript ID
Marker
1
Distance,
Mb
Marker
2
Distance,
Mb
61 GNAT2 AR A 1p13.1 110.15–110.16 NM_005272.3 D1S2651 0.04
62 GPR125 AD RP 4p15.2 22.39–22.52 NM_145290.3 D4S3017 0.92
63 GPR179 AD CSNB 17q21.1 36.48–36.50 NM_001004334 D17S1851 0.41
64 GPR98 AR US 5q14.3 89.85–90.46 NM_032119.3 D5S618 0.08
65 GRK1 AR CSNB 13q34 114.32–114.44 NM_002929.2 D13S1295 1.23 D13S293 0.04
66 GRM6 AR CSNB 5q35.3 178.41–178.42 NM_000843.3 D5S408 1.57 D5S2030 0.6
67 GUCA1A AD CD, CRD 6p21.1 42.12–42.15 NM_000409.3 D6S1582 0.95 D6S1552 0.16
68 GUCA1B AD RP, MD 6p21.1 42.15–42.16 NM_002098.5 D6S1582 0.94 D6S1552 0.19
69 GUCY2D AR/AD LCA, CRD 17p13.1 7.91–7.92 NM_000180.3 D17S1353 0.29
70 HARS AD US 5q31.3 140.05–140.07 NM_002109.4 D5S500 2.2
71 HK1 AD RP 10q22 71.03–71.16 NM_000188.2 D10S1647 0.09
72 IDH3B AR RP 20p13 2.64 NM_006899.3 D20S842 0.05
73 IFT27 AR BBS 22q13.1 37.15–37.17 NM_006860.4 D22S283 0.4
74 IMPDH1 AD RP, LCA 7q31.3-q32 128.03–128.05 NM_000883.3 D7S1875 0.28
75 IMPG1 AD MD 6q14.2-q15 76.63–76.78 NM_001563.2 D6S456 0.52
76 IMPG2 AR RP 3q12.2-q12.3 100.94–101.04 NM_016247.3 D3S1271 0.21
77 INPP5E AD JS, MORM 9q34.3 139.32–139.33 NM_019892.4 D9S1838 1.31
78 IQCB1 AR LCA, SLSN 3q13.33 121.49–121.55 NM_001023570 D3S3576 0.7 D3S3513 2.3
79 ITM2B AD RD 13q14.3 48.81–48.84 NM_021999.4 D13S153 0.05
80 KCNJ13 AR/AD LCA, SVD 2q37.1 233.63–233.64 NM_002242.4 D2S2348 0.51
81 KCNV2 AR CD 9p24.2 2.72–2.73 NM_133497.3 D9S1813 1.4 D9S1858 2.02
82 KIAA1549 AD RP 7q34 138.52–138.67 NM_001164665 D7S684 0
83 KIZ AD RP 20p11.23 21.11–21.23 NM_018474.4 D20S912 0.25
84 KLHL7 AD RP 7p15.3 23.15–23.22 NM_001031710 D7S673 0.63
85 LCA5 AR LCA 6q14.1 80.19–80.25 NM_181714.3 D6S284 0.84
86 LRAT AR RP, LCA 4q32.1 155.66–155.67 NM_004744.3 D4S3021 0.72
87 LRIT3 AD CSNB 4q25 110.77–110.79 NM_198506.3 D4S2945 0.48
88 LRP5 AR/AD FEVR 11q13.2 68.08–68.22 NM_002335.2 D11S4113 0.55
89 LZTFL1 AR BBS 3p21.3 45.86–45.96 NM_020347.2 D3S3582 0.47 D3S3640 2.04
90 MAK AR RP 6p24 10.76–10.84 NM_001242957 D6S470 0.73
91 PRDM13 AD MD 6q14-q16.2 100.05–100.06 N/A D6S1717 0.38
92 MCDR4 AD MD 14q11.2 20.84–21.44 N/A D14S261 0
93 MCDR5 AD MD 19q13.31-q13.32 43.81–47.01 N/A D19S412 0
94 MDDC (CYMD) AD MD 7p21-p15 21.81–30.95 N/A D7S516 0
95 MERTK AR RP, CRD 2q14.1 112.66–112.79 NM_006343.2 D2S2269 0.16
96 MFN2 AD OA 1p36.22 12.04–12.07 NM_014874.3 D1S2667 0.55
97 MFRP AR N, M 11q23.3 119.21–119.22 NM_031433.2 D11S4171 0.16
98 MKKS AR BBS 20p12 10.39–10.41 NM_018848.3 D20S894 0.29
99 MKS1 AR BBS 17q22 56.28–56.30 NM_017777.3 D17S1606 0.68
100 MVK AD RP 12q24 110.01–110.04 NM_000431.2 D12S1645 0
101 MYO7A AR US 11q13.5 76.84–76.93 NM_000260.3 D11S911 0.52
102 NEK2 AD RP 1q32.2-q41 211.83–211.85 NM_002497.3 D1S425 0.23
103 NMNAT1 AD LCA 1p36.22 10.00–10.05 NM_022787.3 D1S223 0.11
104 NPHP1 AR SLSN, BBS 2q13 110.88–110.96 NM_000272.3 D2S1888 0.44
105 NR2E3 AR/AD ESC, RP 15q22.32 72.10–72.11 NM_014249.2 D15S204 0.19
106 NR2F1 AD OA 5q14 92.92–92.93 NM_005654.4 D5S2100 0.89
107 NRL AR/AD RP 14q11.1-q11.2 24.55 NM_006177.3 D14S64 0.01
108 OAT AR Gyrate
atrophy
10q26.13 126.09–126.11 NM_000274.3 D10S1723 0.43
109 OPA1 AD OA 3q28-q29 193.31–193.42 NM_015560.2 D3S3726 1.88
110 OPA4 AD OA 18q12.2-q12.3 39.25–48.06 N/A D18S450 0
111 OPA5 AD OA 22q12.1-q13.1 26.36–36.75 N/A D22S1162 0
112 OPA6 AD MD, RP 8q21-q22 83.62–95.58 N/A D8S270 0
113 OPA8 AD OA 16q21-q22.3 65.07–74.17 N/A D16S3066 0
114 OPN1SW AD Tritanopia 7q31.3-q32 128.41–128.42 NM_001708.2 D7S530 0.78
115 OTX2 AD LCA, M 14q21-q22 57.27–57.28 NM_172337.2 D14S980 0.12
116 PCDH15 AR US 10q21.1 55.56–56.56 NM_033056.3 D10S1788 1.44
117 PDE6A AR RP 5q31.2-q34 149.24–149.32 NM_000440.2 D5S640 0.66
118 PDE6B AR/AD RP, CSNB 4p16.3 0.62–0.66 NM_000283.3 D4S2936 0.03
119 PDE6C AR CD, A 10q23.33 95.37–95.43 NM_006204.3 D10S185 0.18
120 PDE6G AR RP 17q25 79.62 NM_002602.3 D17S928 0.63
121 PDE6H AD Atrophia
areata
12p13 15.13 NM_006205.2 D12S364 1.3
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TABLE 1. Continued
No. Gene/Locus
Inheri-
tance Diseases Location Mb, GRCh37 Transcript ID
Marker
1
Distance,
Mb
Marker
2
Distance,
Mb
122 PITPNM3 AD CRD 17p13 6.35–6.46 NM_031220.3 D17S1874 0
123 PLA2G5 AD BFR 1p36-p34 20.40–20.42 NM_000929.2 D1S2843 0.09
124 PRCD AR RP 17q25.1 74.54–74.54 NM_001077620.2 D17S801 0.03
125 PROM1 AR/AD RP, SMD,
CRD
4p15.32 15.97–16.09 NM_006017.2 D4S3048 0
126 PRPF3 AD RP 1q21.1 150.29–150.33 NM_004698.2 D1S498 0.97
127 PRPF31 AD RP 19q13.42 54.62–54.64 NM_015629.3 D19S572 0.51
128 PRPF4 AD RP 9q31-q33 116.04–116.06 NM_004697.4 D9S1824 0.83
129 PRPF6 AD RP 20q13.33 62.61–62.66 NM_012469.3 D20S173 0.73 D20S171 1.8
130 PRPF8 AD RP 17p13.3 1.55–1.59 NM_006445.3 D17S1828 2.22
131 PRPH2 AD RP, MD, CRD,
LCA
6p21.2-p12.3 42.66–42.69 NM_000322.4 D6S1582 0.41 D6S1552 0.7
132 RAB28 AD CRD 4p15.33 13.37–13.49 NM_004249.3 D4S403 0.26
133 RAX2 AR CRD, MD 19p13.3 3.77–3.77 NM_032753.3 D19S424 0.54
134 RB1 AD Retinoblas-
toma
13q14.2 48.88–49.06 NM_000321.2 D13S153 0
135 RBP3 AR RP 10q11.2 48.38–48.39 NM_002900.2 D10S220 3.96
136 RBP4 AR RPE degen-
eration
10q23.33 95.35–95.36 NM_006744.3 D10S583 0.98
137 RD3 AR LCA 1q32.3 211.65–211.67 NM_183059.2 D1S425 0.41
138 RDH12 AR/AD LCA, RP 14q24.1 68.17–68.20 NM_152443.2 D14S1065 0.71
139 RDH5 AR FA, CD 12q13-q14 56.11–56.12 NM_002905.3 D12S1632 0.3 D12S1724 1.24
140 RGR AR/AD RP 10q23 86.00–86.02 NM_001012720 D10S1717 0.13
141 RGS9 AR DCA 17q24.1 63.13–63.22 NM_003835.3 D17S807 1.64 D17S1809 0.43
142 RGS9BP AR DCA 19q13.12 33.17–33.17 NM_207391.2 D19S868 0.28
143 RHO AR/AD RP, CSNB 3q21-q24 129.25–129.25 NM_000539.3 D3S1290 1.74 D3S3606 0.05
144 RIMS1 AD CRD 6q12-q13 72.92–73.11 NM_014989.5 D6S1681 0.7
145 RLBP1 AR RP, CRD 15q26.1 89.75–89.76 NM_000326.4 D15S979 0.92
146 RNANC AR CRN 10q21 69.99 N/A D10S1652 5.58
147 RP1 AR/AD RP 8q12.1 55.53–55.54 NM_006269.1 D8S1828 1.26
148 RP1L1 AD/AR MD, RP 8p23 10.46–10.51 NM_178857.5 D8S520 0.05
149 RP22 AR RP 16p12.1-p12.3 16.85–24.24 N/A D16S403 0
150 RP29 AR RP 4q32-q34 176.51–183.72 N/A D4S415 0
151 RP32 AR RP 1p21.2-p13.3 101.97–110.88 N/A D1S2651 0
152 RP63 AD RP 6q23 102.44–138.54 N/A D6S457 0
153 RP9 AD RP 7p14.3 33.13–33.15 NM_203288.1 D7S2252 1.06
154 RPE65 AR/AD LCA, RP 1p31.2 68.89–68.92 NM_000329.2 D1S219 0.92
155 RPGRIP1 AR LCA, CRD 14q11.2 21.76–21.82 NM_020366.3 D14S72 0.39
156 SAG AR RP, Oguchi
disease
2q37.1 234.22–234.26 NM_000541.4 D2S2297 1.85 D2S172 1.05
157 SDCCAG8 AR BBS 1q43 243.42–243.66 NM_006642.3 D1S2811 0.03
158 SEMA4A AR RP, CRD 1q22 156.12–156.15 NM_022367.3 D1S305 1.84
159 SLC24A1 AR CSNB 15q22.31 65.94–65.95 NM_004727.2 D15S153 0.61
160 SLC7A14 AR RP 3q26.2 170.18–170.30 NM_020949.2 D3S3723 0 D3S1564 0
161 SNRNP200 AD RP 2q11.2 96.94–96.97 NM_014014.4 D2S2159 0.89
162 SPATA7 AR LCA 14q31.3 88.85–88.90 NM_018418.4 D14S68 0.22
163 TEAD1 AD Atrophia
areata
11p15.2 12.70–12.97 NM_021961.5 D11S1794 0.37
164 TIMP3 AD SRD 22q12.3 33.20–33.26 NM_000362.4 D22S1162 1.05
165 TMEM126A AD OA 11q14.1 85.36–85.37 NM_032273.3 D11S4147 0.83
166 TOPORS AD RP 9p21 32.54–32.55 NM_005802.4 D9S1788 0.59
167 TRIM32 AR BBS 9q33.1 119.45–119.46 NM_012210.3 D9S177 0.99
168 TRPM1 AR CSNB 15q13.3 31.29–31.45 NM_002420.5 D15S165 0.03
169 TSPAN12 AD FEVR 7q31.31 120.43–120.50 NM_012338.3 D7S480 0.47
170 TTLL5 AD CD, CRD 14q24.3 76.13–76.42 NM_015072.4 D14S61 0
171 TULP1 AR RP, LCA 6p21.31 35.47–35.48 NM_003322.3 D6S1645 0.1 D6S439 0.32
172 UNC119 AD CRD 17q11.2 26.87–26.88 NM_005148.3 D17S1824 0.21
173 USH1C AR US 11p15.1 17.52–17.57 NM_005709.3 D11S902 0.03
174 USH1E AD US 21q21 20.94–32.43 N/A D21S1914 0
175 USH1G AR US 17q25.1 72.91–72.92 NM_173477.2 D17S1807 0.55
176 USH1H AD US 15q22-q23 67.34–70.69 N/A D15S980 2.42
177 USH1K AD US 10p11.21-q21.1 35.89–56.09 N/A D10S539 0
178 USH2A AR US, RP 1q41 216.35-216.60 NM_206933.2 D1S2827 0.21
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(ad), and X-linked (xl), as well as rare mitochondrial and
digenic traits.2 Rod or cone photoreceptor degenerations are
two main groups of RDs.
Among the rod RDs, retinitis pigmentosa (RP, MIM no.
268000), a genetically and clinically heterogeneous retinal
degeneration, is the most common worldwide,3 having a
worldwide prevalence estimated to be approximately 1 in
4000 individuals.4–14 Currently, mutations associated with RP
have been identified in more than 82 genes, of which 58 have
been shown to be relevant to arRP (RetNet). However, that
these 82 genes are responsible only for around 60% of RP15,16
suggests that the number of currently unidentified genes
causing RP might be quite high. In addition, the cone RDs,
including cone- or cone–rod dystrophies (CORD) and the
macular dystrophies, which mainly affect the central vision,
have been associated with more than 30 genes (RetNet).
Pakistan has the highest prevalence of consanguineous
marriages in the world, presumably because this practice
provides a number of social and economic advantages.17 In a
review of all published retinal degeneration cases in Pakistan,
only 4 families with compound heterozygous mutations were
identified in 146 (2.7%) genetically resolved arRD families,18
further supporting the utility of homozygosity mapping in this
population. Therefore to identify causative mutations in an
ongoing study of large Pakistani arRD families with multiple
affected individuals, we carried out homozygosity mapping of
known RD loci followed by mutation screening of the genes in
homozygous loci in 67 consanguineous families with arRD from
Pakistan as a part of an ongoing international collaboration
between the National Eye Institute (NEI), National Institutes of
Health (NIH), United States, and the National Centre of
Excellence in Molecular Biology (NCEMB), Allama Iqbal Medical
College, and the National Centre for Genetic Diseases, Shaheed
Zulfiqar Ali Bhutto Medical University in Pakistan.
MATERIALS AND METHODS
Enrollment and Clinical Assessment of arRD
Families
This study was approved by the Institutional Review Boards of
the National Centre of Excellence in Molecular Biology and the
TABLE 1. Continued
No. Gene/Locus
Inheri-
tance Diseases Location Mb, GRCh37 Transcript ID
Marker
1
Distance,
Mb
Marker
2
Distance,
Mb
179 VRD1 AR VRD 22q13 45.96–48.35 N/A D22S1153 0 D22S1170 0
180 ZNF513 AR RP 2p23.3 27.6 NM_144631.5 D2S174 0.76
Based on the Ge´ne´thon map in the National Center for Biotechnology Information, a single microsatellite marker with heterozygosity greater than
0.75 or two markers with heterozygosity less than 0.75 but above 0.5 located within 2 Mb of each candidate gene/locus were selected for each disease
locus. SVD, snowflake vitreoretinal degeneration; SMD, Stargardt-like macular dystrophy; MD, macular dystrophy; CRD, cone–rod dystrophy; ARB,
autosomal recessive bestrophinopathy; FF, fundus flavimaculatus; ESC, enhanced S-cone syndrome; US, Usher syndrome; SLSN, Senior-Loken
syndrome; BCD, Bietti’s crystalline dystrophy; CD, cone dystrophy; BBS, Bardet-Biedl syndrome; OA, optic atrophy; FEVR, familial exudative
vitreoretinopathy; CRN, congenital retinal nonattachment; A, achromatopsia; SFD, Sorsby’s fundus dystrophy; N, nanophthalmols; M, microphthalmus;
KFS, Klippel Feil syndrome; FA, fundus albipunctatus; JS, Joubert syndrome, MORM, MORM syndrome; NIV, neovascular inflammatory
vitreoretinopathy; CODA, cavitary optic disc anomalies; DCA, delayed cone adaptation; VRD, vitreoretinal dystrophy; BFR, benign fleck retina.
FIGURE 1. Workflow of this study.
Pakistani RP Study IOVS j April 2017 j Vol. 58 j No. 4 j 2222
Combined NeuroScience Institutional Review Board at the
National Institutes of Health. Written informed consent
consistent with the tenets of the Declaration of Helsinki was
obtained from participating individuals or their guardians
before the study. Families segregating arRD with three or more
affected individuals were identified by visiting eye hospitals in
Pakistan, mostly in the Punjab. Blood samples were drawn
from potentially informative family members, and genomic
DNA was extracted from leukocytes according to standard
protocols.19 All participants underwent a detailed family,
ophthalmic, and medical history, and selected individuals were
evaluated by visual acuity, best-corrected visual acuity, slit-lamp
biomicroscopy, ophthalmoscopy, fundus photography, and
electroretinography (ERG). Previously, as part of this project,
77 families had been mapped by linkage analysis to specific
chromosomal locations; the causative gene and mutations had
been identified in 62 while for the remaining 15 only the locus
had been identified. For the current homozygosity exclusion
mapping study, 67 families were selected from the remaining
unlinked families based on the availability of DNA samples and
consanguineous marriages of the parents of affected individu-
als. Eight of these families have undergone whole genome
linkage analysis without identified causative genes while the
remaining 59 families were not screened. Families with
possible dominant or X-linked inheritance were excluded,
and some families with only two affected offspring of
consanguineous matings were included in the early parts of
the study.
Homozygosity Mapping and Linkage Analysis
One hundred eighty genes or loci associated with inherited
retinal diseases were selected from RetNet (https://sph.uth.
edu/Retnet/) and screened by homozygosity exclusion
mapping (Table 1). Homozygosity genotyping of 188 micro-
satellite markers was done in one affected individual of each
family. Loci homozygous in the first individual were geno-
typed in a second affected family member and, if also
TABLE 2. Mutations Detected in 67 arRD Families Subjected to Homozygosity Mapping
Fam No. Gene
Mutation Pathogenicity
PhenNucleotide Amino Acid PP2 S C
61220 CDHR1 c.1463delG* p.(G488Afs*20) N/A N/A N/A RP
61166 CEP290 c.148C>T p.(H50Y) PoD DA D EORD
61219 CERKL c.847C>T p.(R283*) N/A N/A N/A RP
61086 CNGA3 c.952G>A p.(A318T) PrD DA D RD
61042 CNGB1 c.2493-2_2495 delinsGGC* p.(S831Rfs*2) N/A N/A N/A RP
61036 CNGB3 c.1148delC* p.(T383Ifs*13) N/A N/A N/A RD
61192 EYS c.6137G>A* p.(W2046*) N/A N/A N/A RP
61016 EYS c.7187G>C p.(C2396S) PrD DA D RP
61015 GRK1 c.55C>T* p.(R19*) N/A N/A N/A RD
61155 GRM6 c.824G>A p.(G275D) PrD DA D CSNB
61058 LCA5 c.652C>G p.(R218G) PrD DA D EORD
61076 LRAT c.418G>T* p.(E140*) N/A N/A N/A RP
61150 NR2E3 c.227G>A p.(R76Q) PrD DA D RP
61217 RBP3 c.3353_3354delCT* p.(S1118Cfs*3) N/A N/A N/A RP
61198 RDH5 c.536A>G p.(K179R) PrD DA D FA
61199 RDH5 c.536A>G p.(K179R) PrD DA D FA
61035 RDH5 c.758T>G p.(M253R) PoD DA D FA
61126 RDH5 c.758T>G p.(M253R) PoD DA D FA
61065 RDH12 c.609C>A p.(S203R) PrD DA D RD
61113 RP1 c.1126C>T p.(R376*) N/A N/A N/A RP
61262 RP1 c.787þ1G>A p.(I263Nfs*8) N/A N/A N/A RP
61231 RPE65 c.119G>A p.(G40D) PrD DA D EORD
61312 RPGRIP1 c.931delA* p.(N311Ifs*5) N/A N/A N/A LCA
61206 TULP1 c.1138A>G p.(T380A) B DA N RP
61301 TULP1 c.1466A>G p.(K489P) PrD DA D EORP
61309 TULP1 c.1466A>G p.(K489P) PrD DA D EORD
61191 USH2A c.5740C>T* p.(Q1914*) N/A N/A N/A RP/D
* Mutation would be expected to result in nonsense-mediated decay.
TABLE 3. Variations of Unknown Significance Detected in Three Genes of 67 arRD Families
No. Fam No. Gene
Variation Pathogenicity
Phen PNucleotide Amino Acid PP2 S C
1 61221 CNGB3 c.1208G>A p.(R403Q) PrD T N RD P
2 61169 LRP5 c.4268C>T p.(P1423L) B T N RD P
3 61237 PROM1 c.1946C>T p.(S649L) B T N RP P
4 61267 PROM1 c.1946C>T p.(S649L) B T N RP P
One homozygous instance of the c.1208G>A, p.(R403Q) variant was identified in 96 healthy individuals. PP2, PolyPhen2; S, SIFT; C, Condel;
PrD, probably damaging; B, benign; T, tolerated; N, neutral; Phen, phenotype; P, progressive; PoD, possibly damaging; DA, damaging; D, deleterious;
N, neutral; N/A, not applicable.
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TABLE 4. Two-Point LOD Scores of arRD Gene Markers in 31 Families
Fam No. Marker Mb 0 0.001 0.01 0.05 0.1 0.2 0.3 0.4 Zmax hmax
61220 D10S1689 85.67 2.63 2.62 2.56 2.3 1.97 1.3 0.66 0.2 2.63 0
D10S1717 85.86 2.86 2.85 2.79 2.53 2.2 1.52 0.87 0.33 2.86 0
CDHR1 c.1463delG, p.(G488Afs*18) 85.95 3.62 3.61 3.55 3.28 2.92 2.18 1.42 0.68 3.62 0
61166 D12S88 86.37 1.91 1.9 1.86 1.69 1.47 1.04 0.62 0.26 1.91 0
CEP290 c.148C>T p.(H50Y) 88.44 2.53 2.53 2.48 2.29 2.04 1.53 1.02 0.51 2.53 0
D12S1598 89.52 1.91 1.9 1.86 1.69 1.47 1.04 0.62 0.26 1.91 0
61219 D2S2310 18.22 1.11 1.11 1.08 0.97 0.84 0.57 0.32 0.13 1.11 0
CERKL c.847C>T, p.(R283*) 18.24 2.41 2.4 2.36 2.19 1.96 1.48 1 0.5 2.41 0
D2S364 18.3 1.88 1.88 1.84 1.68 1.47 1.05 0.64 0.27 1.88 0
61086 D2S2311 99.02 2.03 2.02 1.98 1.8 1.56 1.08 0.61 0.19 2.03 0
CNGA3 c.952G>A, p.(A318T) 98.96 2.53 2.53 2.48 2.29 2.04 1.53 1.02 0.51 2.53 0
D2S2972 102.57 1.12 1.12 1.1 1 0.88 0.62 0.38 0.17 1.12 0
61042 D16S3071 56.66 0.89 0.89 0.86 0.77 0.64 0.4 0.18 0.04 0.89 0
D16S3057 57.52 1.6 1.6 1.56 1.4 1.2 0.8 0.43 0.13 1.6 0
CNGB1 c.2493-2_2495delinsGGC 57.91 1.89 1.89 1.85 1.67 1.45 1 0.56 0.19 1.89 0
D16S3094 59.62 1.6 1.6 1.56 1.4 1.2 0.8 0.43 0.13 1.6 0
D16S514 62.33 0.58 0.58 0.58 0.57 0.53 0.41 0.25 0.11 0.58 0
61036 CNGB3 c.1148delC, p.(T383Ifs*13) 87.59 5.21 5.19 5.09 4.64 4.07 2.87 1.67 0.59 5.21 0
D8S271 88.52 4.72 4.71 4.62 4.18 3.62 2.49 1.37 0.43 4.72 0
D8S270 93.02 ‘ 0.28 0.69 1.23 1.3 1.06 0.65 0.25 1.3 0.1
61221 CNGB3 c.1208G>A, p.(R403Q) 87.59 2.53 2.53 2.49 2.31 2.08 1.59 1.08 0.55 2.53 0
D8S271 88.52 2.21 2.21 2.17 2 1.77 1.31 0.83 0.36 2.21 0
D8S270 93.02 1.91 1.91 1.87 1.69 1.46 1.02 0.6 0.23 1.91 0
61192 D6S402 62.97 2.7 2.7 2.64 2.38 2.05 1.38 0.77 0.27 2.7 0
EYS c.6137G>A, p.(W2046*) 64.43 3.61 3.6 3.54 3.26 2.89 2.14 1.38 0.65 3.61 0
D6S430 67 2.7 2.7 2.64 2.38 2.05 1.38 0.77 0.27 2.7 0
61016 D6S402 62.97 0.29 0.29 0.26 0.17 0.11 0.04 0.02 0.01 0.29 0
EYS c.7187G>C, p.(C2396S) 64.43 0.51 0.5 0.49 0.41 0.32 0.16 0.06 0.01 0.51 0
D6S430 67 0.41 0.41 0.39 0.32 0.25 0.12 0.04 0.01 0.41 0
61015 D13S1295 113.09 1.31 1.3 1.27 1.13 0.95 0.61 0.31 0.1 1.31 0
GRK1 c.55C>T, p.(R19*) 114.32 1.96 1.96 1.92 1.76 1.56 1.13 0.7 0.31 1.96 0
D13S1825 115.01 0.29 0.29 0.28 0.25 0.2 0.11 0.04 0.01 0.29 0
61155 D5S1960 171.51 ‘ 6.05 3.32 1.44 0.78 0.33 0.21 0.13 0.13 0.4
D5S2030 177.81 2.77 2.76 2.7 2.43 2.08 1.4 0.77 0.28 2.77 0
GRM6 c.824G>A, p.(G275D) 178.41 3.56 3.55 3.49 3.2 2.84 2.09 1.34 0.65 3.56 0
D5S2073 178.98 0.74 0.74 0.72 0.65 0.54 0.33 0.15 0.04 0.74 0
D5S408 179.99 1.19 0.71 0.1 0.62 0.7 0.56 0.33 0.13 0.7 0.1
61058 D6S402 62.97 0.9 0.9 0.89 0.81 0.72 0.52 0.3 0.09 0.9 0
D6S284 79.35 0.9 0.9 0.89 0.81 0.72 0.52 0.3 0.09 0.9 0
LCA5 c.652C>G, p.(R218G) 80.19 0.9 0.9 0.89 0.81 0.72 0.52 0.3 0.09 0.9 0
61076 D4S3021 15.49 1.12 1.12 1.09 0.97 0.81 0.51 0.24 0.06 1.12 0
LRAT c.418G>T, p. (E140*) 15.57 1.33 1.33 1.29 1.15 0.98 0.63 0.31 0.08 1.33 0
D4S413 15.84 1.12 1.12 1.09 0.97 0.81 0.51 0.24 0.06 1.12 0
61169 D11S987 67.89 1.62 1.61 1.58 1.43 1.24 0.85 0.47 0.14 1.62 0
LRP5 c.4268 C>T p.(P1423L) 68.08 1.75 1.75 1.72 1.56 1.35 0.93 0.52 0.16 1.75 0
D11S1337 68.13 1.62 1.61 1.58 1.43 1.24 0.85 0.47 0.14 1.62 0
61150 D15S1050 71.98 1.56 1.56 1.52 1.38 1.19 0.84 0.5 0.22 1.56 0
NR2E3 c.417G>A, p.(Q69R) 72.1 2.53 2.53 2.48 2.29 2.04 1.53 1.02 0.51 2.53 0
D15S204 72.3 1.87 1.87 1.83 1.66 1.44 1.01 0.61 0.25 1.87 0
D15S1026 73.66 1.91 1.91 1.87 1.69 1.46 1.02 0.6 0.23 1.91 0
61237 D4S2960 15.83 0.28 0.28 0.27 0.22 0.16 0.06 0.01 0.01 0.28 0
PROM1 c.1946C>T, p.(S649L) 15.97 1.63 1.63 1.59 1.45 1.27 0.93 0.62 0.32 1.63 0
D4S1567 16.46 1.56 1.56 1.53 1.39 1.22 0.91 0.61 0.32 1.56 0
61267 D4S2960 15.83 0.3 0.3 0.29 0.26 0.21 0.13 0.06 0.02 0.3 0
PROM1 c.1946C>T, p.(S649L) 15.97 0.6 0.6 0.58 0.52 0.43 0.27 0.13 0.03 0.6 0
D4S3048 16.01 0.6 0.6 0.58 0.52 0.43 0.27 0.13 0.03 0.6 0
61217 D10S578 37.04 2.92 2.91 2.86 2.62 2.32 1.7 1.08 0.47 2.92 0
RBP3 c.3353_3354delCT, p.(S1118Cfs*2) 48.38 3.26 3.25 3.2 2.95 2.64 1.99 1.33 0.67 3.26 0
D10S196 52.14 2.92 2.91 2.86 2.62 2.32 1.7 1.08 0.47 2.92 0
D10S220 52.35 2.92 2.91 2.86 2.62 2.32 1.7 1.08 0.47 2.92 0
61198 D12S1724 54.87 1.9 1.89 1.85 1.66 1.41 0.91 0.43 0.1 1.9 0
RDH5 c.536A>G, p.(K179R) 56.11 3.44 3.43 3.37 3.08 2.71 1.94 1.15 0.45 3.44 0
D12S1632 56.41 2.25 2.24 2.19 1.96 1.66 1.06 0.51 0.13 2.25 0
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homozygous, in a third affected offspring of consanguineous
parents. When when no single marker with a heterozygosity
of 75% or greater was available, two markers were tested. We
tested two markers within 1 to 2 cM of the candidate gene
with heterozygosities over 50%, but approximately 50% of
families would be expected to show discordant results for
these markers. Thus our assessment was that most discordant
homozygosity would be the result of low information content
rather than recombination between the two markers. Families
uninformative for these markers were genotyped using
additional surrounding markers. Families in which homozy-
gosity was shared only by all affected siblings were further
investigated by genotyping additional individuals for confir-
mation of cosegregation. A variant of the multiplexing short
tandem repeat with tailed primers (MSTP) approach de-
scribed by Oetting et. al.,20 using fluorescently labeled tagged
primers homologous to extensions on initial primers in a two-
PCR approach, was used to genotype these microsatellite
markers. The PCR products were multiplex electrophoresed
on an ABI 3130 Genetic Analyzer (Applied Biosystems, Foster
City, CA, USA), and fragment sizes were determined by
GeneMapper version 4.0 (Applied Biosystems). Primer
sequences and PCR conditions are shown in Supplementary
Table S1.
Two-point linkage analyses were performed using the
FASTLINK modification of the MLINK program in the LINKAGE
program package.21,22 Maximum logarithm of the odds (LOD)
scores were calculated using ILINK, and LINKMAP was used
for multipoint analysis. Autosomal recessive RD was analyzed
as a fully penetrant trait with an affected allele frequency of
0.00001. The criteria for establishing linkage have been
described previously.23 The length of the homozygous regions
TABLE 4. Continued
Fam No. Marker Mb 0 0.001 0.01 0.05 0.1 0.2 0.3 0.4 Zmax hmax
61199 D12S1724 54.87 ‘ 1.15 0.17 0.43 0.59 0.55 0.35 0.13 0.59 0.1
RDH5 c.536A>G, p.(K179R) 56.11 3.17 3.16 3.09 2.81 2.44 1.72 1.02 0.4 3.16 0
D12S1632 56.41 1.73 1.73 1.72 1.63 1.46 1.03 0.56 0.19 1.73 0
61035 D12S1707 55.03 1.35 1.34 1.34 1.08 0.83 0.35 0.02 0.06 1.35 0
RDH5 c.758T>G, p.(M253R) 56.11 1.47 1.47 1.47 1.23 0.99 0.54 0.17 0.01 1.47 0
D12S90 58.42 0.22 0.22 0.22 0.18 0.14 0.05 0.01 0.02 0.22 0
61126 D12S1707 55.03 ‘ 0.75 2.26 2.68 2.56 1.96 1.24 0.57 2.68 0.05
RDH5 c.758T>G, p.(M253R) 56.11 6.42 6.31 6.28 5.72 5.01 3.58 2.21 1.01 6.42 0
D12S90 58.42 4.58 4.51 4.47 4.04 3.51 2.43 1.43 0.6 4.58 0
61065 D14S1065 68.91 2.93 2.92 2.85 2.54 2.15 1.4 0.73 0.23 2.93 0
RDH12 c.609C>A, p.(S203R) 68.17 3.59 3.58 3.51 3.2 2.8 1.98 1.16 0.41 3.59 0
61262 D8S509 55.59 2.35 2.34 2.29 2.09 1.83 1.31 0.8 0.36 2.35 0
RP1 c.787þ1G>A 55.53 2.07 2.07 2.02 1.82 1.55 1.03 0.54 0.15 2.07 0
D8S1828 56.8 2.4 2.4 2.35 2.15 1.89 1.36 0.85 0.37 2.4 0
61113 D8S509 55.59 1.05 1.05 1.04 0.98 0.9 0.7 0.48 0.23 1.05 0
RP1 c.1126C>T, p.(R376*) 55.53 2.84 2.84 2.79 2.58 2.31 1.74 1.15 0.55 2.84 0
D8S1828 56.8 2.02 2.02 1.98 1.81 1.59 1.15 0.7 0.3 2.02 0
61231 D1S2829 6.83 1.2 1.2 1.17 1.04 0.88 0.58 0.3 0.1 1.2 0
RPE65 c.119G>A, p.(G40D) 6.89 1.63 1.63 1.6 1.46 1.28 0.95 0.63 0.33 1.63 0
D1S219 6.98 1.34 1.33 1.3 1.18 1.02 0.72 0.44 0.2 1.34 0
61312 D14S72 21.37 1.78 1.77 1.734 1.57 1.36 0.94 0.55 0.22 1.78 0
D14S1070 21.54 2.28 2.27 2.221 2 1.72 1.16 0.61 0.18 2.28 0
RPGRIP1 c.931delA, p.(N311I*5) 21.76 3.26 3.25 3.201 2.97 2.67 2.05 1.39 0.72 3.26 0
D14S283 22.69 0.78 0.4 0.366 0.88 0.96 0.81 0.53 0.22 0.96 0.1
61206 D6S439 35.15 2.54 2.53 2.48 2.23 1.92 1.31 0.72 0.24 2.54 0
TULP1 c.1138A>G, p.(T380A) 35.46 3.14 3.13 3.08 2.82 2.5 1.82 1.14 0.5 3.14 0
D6S1645 35.58 1.31 1.31 1.29 1.21 1.09 0.82 0.53 0.24 1.31 0
61301 D6S1629 33.79 ‘ 2.39 0.45 0.68 0.94 0.88 0.6 0.25 0.94 0.1
D6S439 35.15 0.8 0.8 0.78 0.69 0.57 0.36 0.19 0.08 0.8 0
TULP1 c.1466A>G, p.(K489R) 35.46 4.46 4.45 4.39 4.08 3.69 2.86 1.98 1.03 4.46 0
D6S1645 35.58 2.35 2.35 2.31 2.1 1.85 1.34 0.83 0.34 2.35 0
D6S291 36.27 3.62 3.61 3.55 3.26 2.88 2.11 1.32 0.52 3.62 0
D6S1610 39.26 ‘ 2.26 0.55 0.59 0.89 0.88 0.59 0.21 0.89 0.1
61309 D6S1629 33.79 2.24 2.24 2.2 2.02 1.78 1.3 0.81 0.34 2.24 0
D6S439 35.15 1.54 1.53 1.51 1.38 1.23 0.91 0.58 0.26 1.54 0
TULP1 c.1466A>G, p.(K489R) 35.46 2.83 2.83 2.79 2.59 2.34 1.81 1.25 0.66 2.83 0
D6S1645 35.58 0.6 0.6 0.58 0.53 0.46 0.32 0.19 0.09 0.6 0
D6S291 36.27 2.24 2.24 2.2 2.02 1.78 1.3 0.81 0.34 2.24 0
D6S1610 39.26 ‘ 3.66 1.89 0.63 0.19 0.09 0.11 0.05 0.11 0.3
61191 D1S425 212.08 ‘ 5.67 2.98 1.16 0 0.06 0.06 0.04 0.06 0.3
D1S2646 214.06 0.7 0.37 0.35 0.76 0.76 0.5 0.24 0.07 0.78 0.07
USH2A c.5740C>T, p.(Q1914*) 215.8 6.27 6.26 6.15 5.67 5.05 3.78 2.47 1.16 6.27 0
D1S2827 216.14 4.06 4.05 3.96 3.57 3.09 2.11 1.18 0.44 4.06 0
D1S229 217.09 3.17 3.16 3.12 2.88 2.56 1.85 1.12 0.47 3.17 0
D1S2860 217.48 4.83 4.82 4.72 4.31 3.78 2.69 1.62 0.69 4.83 0
D1S213 223.82 ‘ 2.55 3.45 3.71 3.44 2.54 1.51 0.57 3.72 0.04
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was 3 Mb on average. Haplotypes were generated using the
Cyrillic 2.1 program (Cyrillic Software, Wallingford, Oxford-
shire, UK) and confirmed by inspection.
Screening Candidate Genes
Based upon cosegregation of the risk haplotypes in a family,
mutations in the exons and 100 bp of flanking intronic regions
of the included known candidate gene associated with
inherited retinal diseases were analyzed by Sanger sequencing
using ABI PRISM 3130 automated sequencers (Applied
Biosystems) and assembled and analyzed with Seqman
software (DNAStar Lasergene 8; Madison, WI, USA) and
Mutation Surveyor (SoftGenetics, State College, PA, USA).
Mutations were submitted to the LOVD (http://databases.
lovd.nl/shared/variants; in the public domain).
Assessing Pathogenicity of Identified Variants
A mutation was considered novel if it was not present in the
Human Mutation Database Professional Version on Biobase
(https://portal.biobase-international.com/cgi-bin/portal/login.
cgi; in the public domain) or the National Center for
Biotechnology Information dbSNP database (http://www.
ncbi.nlm.nih.gov/snp/; in the public domain), and sequence
changes were considered pathogenic when they segregated
with the disease in the family as well as their absence in 192
ethnically matched control chromosomes or at a frequency >
FIGURE 2. Family 61220, 61166, 61219, 61086, 61042 and 61036 structure and haplotype of flanking markers of loci identified by homozygosity
mapping. DNA sequence tracings confirming the mutations are shown adjacent to the pedigrees, and cross-species conservation of amino acids
showing missense mutations is shown on the right.
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1% in the ExAC database (http://exac.broadinstitute.org/; in
the public domain); and for missense changes were judged
pathogenic in a computational test for mutations, including
sorting intolerant from tolerant (SIFT and PROVEAN, http://sift.
jcvi.org/; in the public domain) analysis, polymorphism
phenotyping (PolyPhen2, http://genetics.bwh.harvard.edu/
pph2/; in the public domain), and Condel (http://bg.upf.edu/
fannsdb/; in the public domain). A SIFT score below the cutoff
of 0.05 for a given substitution is classified as damaging while
those with scores higher than this value are considered
tolerated. In addition, we used Condel24 (CONsensus DELete-
riousness score of missense SNVs), which computes a
weighted average of the scores (WAS) of five tools: SIFT,
PolyPhen2, MAPP (Multivariate Analysis of Protein Polymor-
phism), LogR Pfam E-value, and Mutation Assessor. Splicing
changes were predicted using Automated Splice Site Analyses
(http://www.fruitfly.org/seq_tools/splice.html; in the public
domain).
Intragenic Haplotype Analysis for Families
Sharing the Same Variation
If the same variation was detected in more than one family,
haplotypes of single nucleotide polymorphisms (SNPs) intra-
genic or within 1 Mb of the mutated gene were genotyped. The
frequency of the risk haplotype in the general population was
calculated from 96 unrelated Pakistani controls via the CHM
algorithm as implemented in the Golden Helix SVS package
(Golden Helix, Bozeman, MT, USA).
RESULTS
Patient Cohort and Homozygosity Screening
This cohort included 67 consanguineous families with more
than two affected siblings. A total of 67 probands and all
affected siblings or ancestors who received a clinical
FIGURE 3. Family 61221, 61192, 61016, 61015 and 61155 structure and haplotype of flanking markers of loci identified by homozygosity mapping.
DNA sequence tracings confirming the mutations are shown adjacent to the pedigrees, and cross-species conservation of amino acids showing
missense mutations is shown on the right.
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diagnosis of arRP were included in this study. Up to three
affected individuals in each family were subjected to
homozygosity screening in a stepwise manner. After screen-
ing the first affected patient with all 188 microsatellite
markers, the average number of excluded markers for each
family was 126 (126/188 ¼ 67% efficiency), with exclusion
rates of 85% after screening a second affected individual and
93.0% a third, so that the average number of markers to be
analyzed was reduced from 188 to 13 in each family (Fig. 1).
After fine mapping using microsatellite markers, 29 families
were excluded from linkage to any known RP gene, making
the exclusion rate 43.3% for families undergoing homozygos-
ity screening. The remaining 38 families showed homozygos-
ity and cosegregation in at least 1 of the 180 regions
containing known arRD genes or loci.
After sequencing the included candidate genes for which
the remaining 38 families showed homozygosity and cosegre-
gation, the underlying pathogenic mutations were revealed in
27 families (Table 2).25–28 In addition, variations considered
benign by in silico prediction were detected in another four
families (Table 3). The two-point LOD scores for markers in the
homozygous chromosomal segments in these families are
shown in Table 4. In seven families, no variations were
identified by sequencing the known candidate genes within
identified homozygous chromosomal regions, and their signif-
icance remains unclear.
Identification of Disease-Causing Variants in
Homozygous Regions
Overall, 24 causative mutations of 20 genes were identified in
27 families, including 12 missense, 6 nonsense, 4 indel-induced
frameshift mutations, and 2 splice-site mutations (the splicing
FIGURE 4. Family 61058, 61076, 61169, 61150, 61237 and 61267 structure and haplotype of flanking markers of loci identified by homozygosity
mapping. DNA sequence tracings confirming the mutations are shown adjacent to the pedigrees, and cross-species conservation of amino acids
showing missense mutations is shown on the right.
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site change in CNGB1 was induced by an indel mutation). In
all, 11 mutations were novel, and were not found in mutation
databases or in 192 ethnically matched control chromosomes,
while the remaining 13 mutations had been reported
previously. Each of the mutations was located within a
homozygous region and cosegregated with the disease. For
missense mutations, the substituted amino acid residues are
highly conserved across species (Figs. 2–7), and in silico
pathogenicity evaluation by PolyPhen2, SIFT, and Condel of the
12 missense mutations predicted these changes to be
deleterious. Some variations were detected in two families,
including c.536A>G (p.(K179R), family 61198 and 61199) and
c.758T>G (p.(M253R), family 61035 and 61126) in RDH5,
c.1466A>G (p.(K489P), family 61301 and 61309) in TULP1,
and the probably nonpathogenic c.1946C>T (p.(S649L), family
61237 and 61267) in PROM1. Affected families who shared the
same variations also shared a common haplotype of alleles at
nearby intragenic SNPs, suggesting that the mutant allele was
probably derived from a common ancestor (Supplementary
Table S2). Although genes or loci previously associated only
with autosomal dominant inherited retinal disease were also
screened in the study, no mutations were identified in these
genes or loci.
Details of Sequence Variations Identified by
Homozygosity Mapping
Information regarding the 24 sequence variations felt likely to
be causative identified by homozygosity screening, and
phenotypes of the 27 families in which they occurred, is
FIGURE 5. Family 61217, 61065, 61198, 61199,61035 and 61126 structure and haplotype of flanking markers of loci identified by homozygosity
mapping. DNA sequence tracings confirming the mutations are shown adjacent to the pedigrees, and cross-species conservation of amino acids
showing missense mutations is shown on the right.
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provided in Table 2, and similar information for variations
judged likely to be benign based on in silico predictions or
presence in unaffected control individuals is provided in
Table 3. The domain structure of the corresponding proteins
and locations of the mutations with respect to these are
shown in Figures 8 and 9, while the pedigree structure and
corresponding haplotypes as well as sequence tracings and
cross-species conservation for missense changes are shown in
Figures 2 through 7, with the corresponding LOD scores
summarized in Table 4.
Details of Sequence Variations Considered Likely
to Be Deleterious
The c.847C>T, p.(R283*) mutation in CERKL seen in family
61219 is predicted to lead to truncation of the protein
through a premature stop codon, and might be expected to
lead to nonsense-mediated decay. However, this mutation has
been shown to cause accumulation of truncated protein in
the nucleus.29 The c.55C>T, p.(R19*) mutation in GRK1 seen
in family 61015 was predicted to lead to truncation of GRK1
protein and result in nonsense-mediated decay, and seems
likely to result in a variant form of Oguchi disease, as
described by Zhang et al.,30 also predicted to result in
nonsense-mediated decay; however, detailed clinical data
sufficient for this diagnosis could not be obtained, so it is
listed in Table 2 as having a stationary RD. Family 61058
(Table 2) contains a c.652C>G, p.(R218G) mutation in LCA5
segregating in a pseudo-dominant inheritance pattern, but the
recessive nature of the mutation is confirmed by the
sequencing results (Fig. 4). The c.227G>A p.(R76Q) mutation
in the DNA-binding domain (DBD) of NR2E3 (Fig. 9) had been
shown to increase dimerization significantly but to abolish
DNA binding.31
FIGURE 6. Family 61113, 61262, 61231, 61312 and 61206 structure and haplotype of flanking markers of loci identified by homozygosity mapping.
DNA sequence tracings confirming the mutations are shown adjacent to the pedigrees, and cross-species conservation of amino acids showing
missense mutations is shown on the right.
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Details of Sequence Variations Considered Likely
to Be Benign
The previously described missense variation c.1208G>A,
p.(R403Q) in CNGB332 seen in family 61221 (Fig. 3) was
identified in a homozygous state in 1 of 96 control individuals.
It was predicted to be probably damaging by PolyPhen2 but
tolerated by SIFT and neutral by Condel, so it seems most likely
only to be a rare variation (Table 3), although a modifying gene
affecting the phenotype cannot be excluded. The novel
c.4268C>T, p.(P1423L) variation in LRP5 was in an amino
acid evolutionarily conserved from humans to zebrafish (Figs.
4, 9), had an allele frequency of 2.529 3 105 in the ExAC
browser with no homozygotes listed in any population, and
was not seen in 96 control individuals of Pakistani ethnic
extraction. However, in silico analysis with PolyPhen2 predict-
ed that it would be benign, with SIFT showing that it was
tolerated, and Condel that it was neutral (Table 3). Hence, we
treated this change as a rare variation even though the
possibility that it might be responsible for disease in this
family remains, especially since the phenotype in this family
was progressive, consistent with a less severe mutation.
A novel missense variation c.1946C>T, p.(S649L) in
PROM1 was detected and cosegregated with the disease in
families 61237 and 61267 (Table 3; Fig. 4). S649 is only
weakly conserved from human to chicken, but the substitu-
tions, from serine to threonine, are relatively conservative
(Fig. 4). This mutation does not occur in a transmembrane
domain (Fig. 9) and is predicted to be benign by three in silico
analyses. Thus, we presumed that this mutation is a rare
variation, even though p.(S649L) was not found in 192
control chromosomes from the Pakistani population and had
an overall frequency of 5.456 3 105 in the ExAC database,
with all six variant alleles identified in the South Asian
population with no homozygotes. Affected members of the
two families share a common haplotype of alleles at 10
consecutive SNPs in and around PROM1 suggesting that the
variant allele is derived from a common ancestor (Supple-
mentary Table S2).
Clinical Features
An overview of the clinical data from affected individuals in
each family is shown in Table 2. The clinical symptoms, age of
onset, and mode of inheritance in these families are generally
FIGURE 7. Family 61301, 61309 and 61191 structure and haplotype of flanking markers of loci identified by homozygosity mapping. DNA sequence
tracings confirming the mutations are shown adjacent to the pedigrees, and cross-species conservation of amino acids showing missense mutations
is shown on the right.
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consistent with the form of retinal degeneration described in
the literature and on RetNet. However, the clinical data
available for this study are limited to ophthalmic history and
examination, fundus photographs, and ERGs, so that it is
difficult to distinguish closely related forms of the retinal
disease, for example, Leber congenital amaurosis (LCA) or
CORD from RP. Thus, we use RD to represent those families in
which the clinical findings are consistent with the previously
described retinal disease, but were insufficient to distinguish
unambiguously among the various diseases previously associ-
ated with that gene: RP, LCA, congenital stationary night
blindness (CSNB), or fundus albipunctatus, which together
account for 8 of 27 (30%) families. Four of these had an early
onset, but the differentiation between early-onset arRP and
LCA, difficult with the best documentation, could not be made
reliably. Thirteen families showed clear signs of RP. One family
was consistent with LCA with typical fundoscopy, extinguished
ERGs, and a history of a congenital onset accompanied by
nystagmus. Four families that carried a homozygous RDH5
mutation received a diagnosis of fundus albipunctatus by
fundus photographs. Of the remaining two families, one
showed the typical signs of CSNB without progression, and
the second was consistent with Usher syndrome (RP with
deafness). Although there was no indication of vestibular
dysfunction in any affected individual in this family, suggesting
Usher type 2 and consistent with the causative gene, this was
simply listed as Usher syndrome because formal vestibular
testing was not performed.
DISCUSSION
Consanguineous matings have long been known to increase
the risk of recessive diseases by increasing the fraction of the
genome that is homozygous and identical by descent, and thus
the number of potentially deleterious alleles descended from a
common ancestor33; and homozygosity mapping provides an
efficient means of localizing causative genes for recessive traits
in these populations,34 particularly in populations with high
consanguinity rates. Pakistan, with consanguinity rates ranging
from 17% to 38%,35 is an optimal country in which to
implement this approach.
In addition, the clinical phenotypes for some families are of
particular interest. One such was family 61015, shown in Table
2 as having a stationary form of RD. The phenotype in this
family, as far as it could be ascertained, was consistent with
mutations in GRK1 causing Oguchi disease and was similar to
that in a previous Pakistani family with a variant of Oguchi
disease due to deletion of exon 3,30 although the degree of
recovery from dark adaptation could not be ascertained in this
FIGURE 8. Domain structure and mutations of proteins in which mutations were identified by homozygosity mapping: CDHR1, CEP290, CERKL,
CNGA3, CNGB1, CNGB3, EYS, GRK1, GRM6, LCA5.
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family. Thus, it is listed simply as a stationary RD, even though
it is very likely to have Oguchi type CSNB. Another was family
61150, with a mutation in NR2E3. This gene primarily has been
associated with enhanced S-cone syndrome and Goldmann-
Favre syndrome. However, the phenotype in family 61150 is
most consistent with progressive arRP, similar to that observed
in a family of Portuguese ‘‘crypto-Jews’’ with a mutation in this
gene.36 In addition, Sharon et al.37 have described NR2E3
mutations in a series of patients with clumped pigmentary
retinal degeneration, who also might be consistent with the
phenotype observed in this family.
Taken together with our previous characterization of
autosomal recessive retinal degenerations (arRD) in Pakistan,
we have studied a total of 144 consanguineous arRD families,
in addition to 154 families with limited numbers of affected
individuals or unclear inheritance patterns. Of these 144
families, we have identified putative causative variations in 40
genes and 11 loci so far, and these genes and loci collectively
account for disease in 104 of the 144 families (72.2%) (Table 5;
Fig. 10). The percentages of families who had variants in the 40
genes and 11 loci are shown in Figure 10, in decreasing order:
RPE65 6.9% (10/144), TULP1 6.9% (10/144), RP1 4.9% (7/
144), PDE6A and locus 4.9% (7/144), USH2A and new locus
3.5% (5/144), RDH5 2.8% (4/144), 11p11.2-q13.2 locus 2.1%
(3/144), GRM6 2.1% (3/144), and 1p13.3 locus 2.1% (3/144). It
should be noted that this tabulation counts families sharing an
intragenic haplotype as separate families. Other genes or loci
were identified in only one or two families in this cohort,
respectively, accounting for less than 2% of the arRD
population in Pakistan.
The most frequently mutated genes in arRD differ remark-
ably among the populations of different ethnic origins. RPE65
and TULP1 were the genes most frequently mutated in
Pakistani patients with arRD, while the genes found to be
most frequently mutated in other populations were RP1 in
Saudi Arabians,38 RDH12 in Spanish,39 and USH2A world-
wide.15 The overall rate of variant detection was 61.8% (89/
144) in this study, which is comparable to the worldwide
FIGURE 9. Domain structure and mutations of proteins in which mutations were identified by homozygosity mapping: LRAT, LRP5, NR2E3, PROM1,
RBP3, RDH5, RDH12, RP1, RPE65, RPGRIP1, TULP1, USH2A.
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TABLE 5. Sequence Variations Identified in 144 Unselected Pakistani Families
No. Fam # Gene Nucleotide AA Dis Prog Reference
1 61004 IMPDH1 c.931G>A p.(D311N) RP Prog 50
2 61006 RP1 c.4555delA p.(R1519fs*2) RP Prog 51
3 61014 BBS2 c.1237C>T p.(R413*) RP Prog 52
4 61015 GRK1 c.55C>T p.(R19*) RD Sta This study
5 61016 EYS c.7187G>C p.(C2396S) RP Prog 43
6 61019 PDE6A c.769C>T p.(R257*) RP Prog 53
7 61020 RPE65 c.95–1G>A N/A RD Prog 54
8 61021 PDE6A c.2098dupT p.(Y700Lfs*21) RP Prog 53
9 61029 GRK1 c.827þ623_883del p.(Y277Qfs*6). OD Sta 30
10 61032 AIPL1 c.773G>C p.(R258P) RD Prog 55
11 61035 RDH5 c.758T>G p.(M253R) FA Sta 27
12 61036 CNGB3 c.1148delC p.(T383Ifs*13) RD Prog 42
13 61037 PROM1 c.1726C>T p.(Q576*) RP Prog 56
14 61039 CNGA1 c.626_627delTA p.(I209Sfs*26) RP Prog 57
15 61040 RP1 c.1458_1461dup p.(E488*) RP Prog 51
16 61042 CNGB1 c.2493-2_2495delinsGGC p.(S831Rfs*2) RP Prog 41
17 61043 RP1 c.5252delA p.(N1751fs*4) RP Prog 51
18 61049 BBS3 c.123þ1118del53985 N/A* RP Prog 58
19 61058 LCA5 c.652C>G p.(R218G) EORD Prog This study
20 61061 11p11.2-q13.2 N/A N/A RP Prog †
21 61063 TULP1 c.1138A>G p.(T380A) RP Prog 59
22 61064 RLBP1 c.466C>T p.(R156*) FA Sta 60
23 61065 RDH12 c.609C>A p.(S203R) RD Prog 47
24 61070 SLC24A1 c.1613_1614delTT p.(F538Cfs*23) CSNB Sta 61
25 61074 PDE6A c.1408-2A>G p.(K470_L491del) RP Prog 53
26 61076 LRAT c.418G>T p.(E140*) RP Prog This study
27 61077 GUCY2D c.2384G>A p.(R795Q) EORD Prog 41
28 61078 LCA5 c.1151delC p.(P384Qfs*18) EORD Prog 41
29 61081 PDE6A locus N/A N/A RP Prog 53
30 61084 TULP1 c.1466A>G p.(K489R) RP Prog 59
31 61086 CNGA3 c.952G>A p.(A318T) RD Prog This study
32 61103 GUCY2D c.2189T>C p.(F730S) RD U 41
33 61104 11p11.2-q13.1 N/A N/A RP Prog †
34 61107 RLBP1 c.346G>C p.(G116R) FA Sta 60
35 61111 TULP1 c.1466A>G p.(K489R) RP Prog 59
36 61113 RP1 c.1126C>T p.(R376*) RP Prog This study
37 61115 ZNF513 c.1015T>C p.(C339R) RP Prog 62
38 61116 RPE65 c.963T>G, c.782T>C p.(N321K), p.(L261P) RD Prog †
39 61117 RP1 c.3697delT p.(S1233Pfs*22) RP Prog 48
40 61120 LRAT c.538A>T p.(K180*) RP Prog †
41 61122 TULP1 c.1466A>G p.(K489R) RP Prog 59
42 61124 PDE6A c.769C>T p.(R257*) RP Prog 53
43 61125 OAT locus N/A N/A RD Prog †
44 61126 RDH5 c.758T>G p.(M253R) FA Sta 27
45 61129 SAG locus N/A N/A RD Prog †
46 61130 GNAT1 c.386A>G p.(D129G) CSNB Sta 63
47 61133 PDE6A c.2028-1G>A p.(K677Rfs*24) RP Prog 64
48 61138 USH2A c.11473delC p.(H3825Ifs*10) RP/D Prog 41
49 61140 PDE6A c.1408-2A>G p.(K470_L491del) RP Prog 53
50 61141 USH2A c.4645C>T p.(R1549*) RD U 41
51 61142 CNGB1 c.2493-2_2495delinsGGC p.(S831Rfs*2) RP Prog 41
52 61147 TTPA locus N/A N/A RP Prog †
53 61150 NR2E3 c.227G>A p.(R76Q) RP Prog 45
54 61151 USH2A locus N/A N/A RP/D Prog †
55 61155 GRM6 c.824G>A p.(G275D) CSNB Sta 44
56 61157 RP1 c.6098G>A p.(C2033Y) RP Prog †
57 61160 RPE65 c.179T>C p.(L60P) RD Prog 54
58 61161 PDE6b c.1655G>A p.(R552Q) RP Prog 65
59 61166 CEP290 c.148C>T p.(H50Y) EORD Prog This study
60 61167 11p11.2-q13.1 N/A N/A RP Prog †
61 61170 GRM6 c.1336C>T p.(R446*) CSNB Sta 66
62 61171 TULP1 c.1466A>G p.(K489R) RP Prog 59
63 61172 GRM6 c.2267G>A p.(G756D) CSNB Sta 67
64 61173 MERTK c.718G>T p.(E240*) RP Prog 68
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variation detection rate of 60%.15 A recent report that
summarized 103 published Pakistani RD families18 found
AIPL1 and CRB1 to be the most frequent causative genes,
probably because LCA families accounted for approximately
20% of the arRD families, while there were significantly fewer
LCA families in our patient cohort. In addition, the previous
summary included families screened by sequencing previously
identified candidate genes, which might tend to favor those
genes identified early and/or widely publicized. In our study,
sharing of variations by different families is likely to be the
result of the variant allele being derived from a common
ancestry, since all of the families that shared the same variation
also shared common intragenic SNP haplotypes for the
associated gene. In addition, although we included the 79
genes/loci reportedly responsible only for autosomal dominant
RD, no mutations were identified in genes previously
associated only with adRD.
Taken together, we failed to uncover the pathologic
variation in 27.8% of families in our arRD patient cohort.
Although 38 families showed homozygosity and cosegregation
in at least 1 of the 180 regions containing known arRD genes or
loci, no disease-causing mutations were identified in 11 of
these, so that they are excellent candidates for identification of
new arRD genes residing within linked regions in which no
mutations were identified in the known candidate gene. The
most promising approach to discover novel genes after such a
systematic analysis of many consanguineous families is next-
generation sequencing, although familial locus heterogeneity
or compound heterozygous mutations might explain the
phenotype of a small proportion of the families, as intrafamilial
locus heterogeneity was detected in 15.3% of the families
studied in a recent report of Pakistani families with hearing
impairment.40 In addition, compound heterozygous mutations
were identified in 2.7% of genetically resolved arRD families in
a review of all published retinal degeneration cases in
Pakistan.18 Although homozygosity mapping has been proven
effective, a major limitation is that this type of analysis will
overlook familial locus heterogeneity or compound heterozy-
gous mutations.
In conclusion, homozygosity mapping of known genes is
relatively inexpensive while still being accurate and compre-
hensive. Our results provide a key bridge between bench and
bedside and should make genetic diagnosis of arRD in patients
more accessible and practical. This should greatly enhance the
clinical genetic counseling, diagnosis, and early intervention of
arRD in the Pakistani population. These results also highlight
the importance of analyzing the causative genes and their
exons in different ethnic groups in a systematic and
population-specific fashion.
TABLE 5. Continued
No. Fam # Gene Nucleotide AA Dis Prog Reference
65 61176 FAM161A c.1600A>T p.(R534W RP Prog 41
66 61179 BBS8 c.115-2A>G p.(E39_Q48del) RP Prog 69
67 61183 PDE6b c.1160C>T p.(P387L) RP Prog 70
68 61185 USH2A c.12523T>G p.(W4175G) RP/D Prog 41
69 61186 CRB1 c.433T>C p.(C145R) RD Prog †
70 61191 USH2A c.5740C>T p.(Q1914*) RP/D Prog This study
71 61192 EYS c.6137G>A p.(W2046*) RP Prog This study
72 61198 RDH5 c.536A>G p.(K179R) FA Sta 46
73 61199 RDH5 c.536A>G p.(K179R) FA Sta 46
74 61206 TULP1 c.1138A>G p.(T380A) RP Prog 28
75 61217 RBP3 c.3353_3354delCT p.(S1118Cfs*3) RP Prog This study
76 61219 CERKL c.847C>T p.(R283*) RP Prog 26
77 61220 CDHR1 c.1463delG p.(G488Afs*20) RD Prog 25
78 61227 AIPL1 c.465G>T p.(Q155H) RD Prog 55
79 61231 RPE65 c.119G>A p.(G40D) EORD Prog This study
80 61235 RPE65 c.361delT p.(S121Lfs*6) EORD Prog 54
81 61239 FAM161A c.1139G>T p.(R380L) RP Prog †
82 61259 TULP1 c.1561C>T p.(P521S) RP Prog 71
83 61262 RP1 c.787þ1G>A p.(I263Nfs*8) RP Prog 48
84 61268 TULP1 c.1495þ4A>C p.(P499Rfs*104) RP Prog 49
85 61274 BBS12 c.1616G>T p.(G539V) RP/D Prog †
86 61281 RPE65 c.1087C>A p.(P363T) RD U 46
87 61282 RPE65 c.1087C>A p.(P363T) RD U 41
88 61283 RPE65 c.1087C>A p.(P363T) RD U 41
89 61284 RPE65 c.1087C>A p.(P363T) RD U 41
90 61285 RPE65 c.1087C>A p.(P363T) RD U 41
91 61289 CDHR1 c.1463delG p.(G488Afs*20) RP Prog 25
92 61301 TULP1 c.1466A>G p.(K489R) EORP Prog 49
93 61309 TULP1 c.1466A>G p.(K489R) EORP Prog 49
94 61312 RPGRIP1 c.931delA p.(N311Ifs*5) LCA Sta this study
95 61324 SAG c.874C>T p.(R292*) RD U 72
96 61373 CERKL c.847C>T p.(R283*) RD U 26
97 61376 PRCD c.2T>C p.(M1T) RP Prog 73
AA, amino acid; Dis, disease; OD, Oguchi disease; RP, retinitis pigmentosa; FA, fundus albipunctatus; EORD, early-onset RD; RP/D, RP with
deafness; EORP, early-onset RP; N/A, not available; Prog, progressive; Sta, stationary; U, unknown.
* Deletion beginning in intron 3 and extending beyond end of the BBS3 gene.
† Riazuddin S, written communication, 2017.
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